DN42 access
本服务为那些无法轻松访问自身网络的用户以及希望体验 dn42 但又不想承担维护自有网络成本的用户提供 dn42 连接
默认情况下，地址从/96地址块中分配，如果您希望租用独立的/96前缀或更大的地址空间，请按照联系方式联系我
所有公开的PoP均已屏蔽来自中国境内的 IP 地址。如果您确实需要dn42 access，请与我联系并提供合理的理由
该服务由AS4242423377提供
- - - - - - -
The service provides DN42 connectivity to members who cannot easily access their own networks, as well as to those who would like to explore DN42 without the overhead of maintaining their own network.
By default, addresses are allocated from a /96 block. If you wish to lease a dedicated /96 prefix or a larger address space, please contact me using the methods provided in the contact information.
All publicly accessible PoP are blocked for IPs originating from within China. DN42 access from within China is not publicly available. If you genuinely require access, please contact me and provide a valid justification.
Hosted by AS4242423377.
Policy
本服务需要花费时间和金钱才能运行，但为了您的利益，我们免费提供。使用本服务是一种特权，而非权利。您必须合理使用本服务，以确保其他用户也能继续享受同样的便利。任何滥用、误用或干扰服务或其他用户的行为都可能导致您的访问权限立即被暂停或终止。
滥用行为包括但不限于：
- 过度使用资源
- 黑客攻击、病毒、木马等，或任何其他可能损害服务或对服务及其用户造成风险的干扰行为
- 传播可能导致民事或刑事责任的不良内容
- - - - - - -
This service require real time and financial resources to operate, yet are provided free of charge for your benefit. Access to the services is a privilege, not a right. You must use the services responsibly and considerately to ensure that other users can continue to enjoy the same opportunities. Any misuse, abuse, or activities that disrupt the service or other users may result in immediate suspension or termination of access.
Abuse could include, but is not limited to:
- Excessive use of resources
- Hacking, viruses, trojans etc or any other disruption that could harm or create risk to the services or its users
- Distribution of objectional content that could create a civil or criminal liability
PoP
## Toronto, Canada
Prefix: fdb6:fc6a:e66c:724f:fad1:d2cf::/96
Zerotier: 4753cf475f65b0fb
## Los Angeles, USA
coming soon
#announcement#service
In Japan, a marketing campaign called 'kokoro no kaze' (a cold of the soul) was used to promote antidepressants, increasing sales sixfold. It falsely suggested depression was simple and temporary like a cold, hiding the true treatment needs. This led to over-medication and potential harm. Now, companies focus on bipolar disorder, risking similar issues. 🚨💊
[Read more]
@googlefactss
#MentalHealth#Japan#Pharmaceuticals#Depression#Bipolar#HealthRisks
🚀 Hong Kong's Innovative Drug Sector Gains Momentum
Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends.
#HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment
$2.16M Fundraising by Umecrine
Umecrine Cognition, a Swedish clinical-stage pharmaceutical firm, has raised $2.16 million to advance its innovative drug development targeting neurological disorders. The funding round took place on December 19, 2024.
#UmecrineCognition#Pharmaceuticals#NeurologicalDisorders#Funding#Healthcare#ClinicalStage#Sweden
Massive Funding Rounds Highlight Emerging Tech
🔍 Recent funding rounds spotlight key players in various industries:
- Zenith Energy: $1.18B for remote off-grid and urban microgrid power solutions. More Info
- Kommunalkredit Austria: $209.71M investment to enhance societal quality of life. More Info
- Hanyang Technology: Secured $200M, focusing on technology development. More Info
- Duetti: $200M to revolutionize music catalog acquisitions from independent artists. More Info
- Peregrine Technologies: $190M aimed at improving public safety management. More Info
- TK Elevator: $166.05M raised to enhance elevator technology. More Info
- Zhipu AI: $137.27M funding for AI development, including high-precision knowledge maps. More Info
- Geneus: $100M dedicated to science and technology advancements. More Info
- Swap: $40M for enhancing ecommerce shipping and tracking. More Info
- Atmosic: $40M for innovative battery-less technology solutions. More Info
- Ocean Yield: $35M for investments in maritime assets. More Info
- Viam: $30M towards AI and automation engineering solutions. More Info
- Coalition: $30M for cybersecurity insurance and services. More Info
- Danking Pharmaceuticals: $20.59M focused on innovative pharmaceutical research. More Info
- IdentifySensors: $20M for biomarker detection technology. More Info
- LlamaIndex: $19M for developing AI knowledge assistants. More Info
- Heidi Health: $16.60M for AI-driven healthcare documentation. More Info
- Prime Intellect: $15M for accessible AI development platforms. More Info
#AI#VC#Energy#Tech#Pharmaceuticals#Ecommerce#Cybersecurity#Music#PublicSafety#Automation#HealthTech
🚀 Germany's Industrial Output Falls Unexpectedly in February
Germany's Federal Statistical Office announced on Thursday that industrial output in February unexpectedly declined, with energy price shocks from Middle Eastern conflicts expected to further suppress production. According to Jin10, industrial output fell by 0.3% month-on-month in February, following a revised flat reading in January. The market had generally anticipated a 0.5% increase for February. The decline in output was primarily driven by decreases in the construction sector, as well as in the electronics, optical products, and pharmaceutical industries. In contrast, the Federal Statistical Office noted that automobile production saw growth after a significant drop in January.
#Germany#IndustrialOutput#Economy#Manufacturing#Construction#Electronics#Pharmaceuticals#Automobile#EnergyPrices#February
$140M Funding for Ottimo Pharma
Ottimo Pharma announces a funding round of $140 million set for December 19, 2024. The company focuses on developing bi-functional medicines aimed at improving the lives of individuals living with cancer.
Learn more
#Funding#OttimoPharma#Cancer#BiFunctionalMedicines#Healthcare#Pharmaceuticals#LifeSciences#Investments#MedicalResearch#Oncology#HealthTech#Biotechnology
PeproMene Bio Secures $11M Round
PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders.
More info: PeproMene Bio
#Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment
Turn Therapeutics Secures $75M Funding
Turn Therapeutics, specializing in advanced wound and dermatologic care, has raised $75 million in funding. The investment aims to boost their innovative pharmaceutical and medical device offerings using proprietary technology. For more details, visit their website: Turn Therapeutics.
#Funding#Biotech#Healthcare#Pharmaceuticals#MedicalDevices#WoundCare#Dermatology#Investment#Innovation#Technology#TurnTherapeutics#Proprietary#AdvancedCare#Medical#Company#Therapeutics#Research#Development#Startups
$4.07M Funding for PeptiSystems
PeptiSystems secured $4.07M in funding on December 20, 2024. The company develops advanced instruments for solid-phase synthesis in peptide and oligonucleotide therapeutics, catering to both GMP and non-GMP manufacturing. Discover more: PeptiSystems
#Funding#PeptiSystems#Therapeutics#Peptides#Oligonucleotides#GMP#Manufacturing#Synthesis#Biotechnology#Pharmaceuticals#MedicalDevices#FlowthroughColumnTechnology#ProcessDevelopment#LifeSciences